NASDAQ:ZSANZosano Pharma Stock Price, Forecast & News

Zosano Pharma's stock was trading at $0.5662 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ZSAN stock has increased by 74.8% and is now trading at $0.99. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zosano Pharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Zosano Pharma.

Zosano Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Zosano Pharma.

Zosano Pharma Corp (NASDAQ:ZSAN) posted its quarterly earnings data on Thursday, May, 14th. The biotechnology company reported ($0.24) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.28) by $0.04. View Zosano Pharma's earnings history.

Zosano Pharma's stock reverse split on Friday, January 26th 2018. The 1-20 reverse split was announced on Thursday, January 25th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 25th 2018. An investor that had 100 shares of Zosano Pharma stock prior to the reverse split would have 5 shares after the split.

4 brokerages have issued 12 month price objectives for Zosano Pharma's shares. Their forecasts range from $2.00 to $7.00. On average, they anticipate Zosano Pharma's stock price to reach $4.75 in the next twelve months. This suggests a possible upside of 379.8% from the stock's current price. View analysts' price targets for Zosano Pharma.

News articles about ZSAN stock have been trending very negative this week, according to InfoTrie. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Zosano Pharma earned a media sentiment score of -3.1 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutZosano Pharma.

Some companies that are related to Zosano Pharma include Gemphire Therapeutics (GEMP), Kalvista Pharmaceuticals (KALV), Lexicon Pharmaceuticals (LXRX), Paratek Pharmaceuticals (PRTK), NuCana (NCNA), IVERIC bio (ISEE), Chimerix (CMRX), Aravive (ARAV), vTv Therapeutics (VTVT), Nature's Sunshine Products (NATR), Aduro BioTech (ADRO), Kindred Biosciences (KIN), NeuBase Therapeutics (NBSE), Avenue Therapeutics (ATXI) and TAIWAN LIPOSOME/S (TLC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Zosano Pharma investors own include Amplify Energy (AMPY), Amplify Energy (AMPY), AEterna Zentaris (AEZS), Titan Pharmaceuticals (TTNP), Ekso Bionics (EKSO), Hallador Energy (HNRG), Miragen Therapeutics (MGEN), ADMA Biologics (ADMA), BioNano Genomics (BNGO) and Matinas BioPharma (MTNB).

(ZSAN) raised $47 million in an initial public offering on Tuesday, January 27th 2015. The company issued 4,300,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO.

Zosano Pharma trades on the NASDAQ under the ticker symbol "ZSAN."

Zosano Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Telemetry Investments L.L.C. (4.80%), BlackRock Inc. (0.71%), Sabby Management LLC (0.37%) and UBS Group AG (0.18%). View institutional ownership trends for Zosano Pharma.

ZSAN stock was purchased by a variety of institutional investors in the last quarter, including Telemetry Investments L.L.C., Sabby Management LLC, UBS Group AG, and BlackRock Inc.. View insider buying and selling activity for Zosano Pharma.

Shares of ZSAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ZSAN stock can currently be purchased for approximately $0.99.

Zosano Pharma has a market capitalization of $53.80 million. The biotechnology company earns $-37,590,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis. Zosano Pharma employs 53 workers across the globe.

The official website for Zosano Pharma is www.zosanopharma.com.

Zosano Pharma's mailing address is 34790 ARDENTECH COURT, FREMONT CA, 94555. The biotechnology company can be reached via phone at 510-745-1200 or via email at [email protected]